Strides Pharma Science Limited Board Recommends Change in Statutory Auditors
Strides Pharma Science Limited announced that its Board of Directors, following a meeting held on May 18, 2026, has recommended the appointment of M/s. Deloitte Haskins & Sells LLP as the company's Statutory Auditors for a term of five consecutive years.The recommendation follows the conclusion of the second term for the existing auditors, M/s. B S R & Co. LLP, Chartered Accountants.
The Board’s consideration and recommendation were based on the advice of the Audit Committee.
Auditor Appointment Details
The appointment of Deloitte Haskins & Sells LLP is set to take effect from the conclusion of the 36th Annual General Meeting (AGM) in 2027 and is projected to continue until the conclusion of the 41st AGM in 2032.The firm initiating the change is M/s. B S R & Co. LLP, Chartered Accountants (Firm Registration No. 101248W/ W-100022), whose second term of five consecutive years will conclude at the 36th AGM in 2027.
| Particular | Details |
|---|---|
| Incoming Auditor | M/s. Deloitte Haskins & Sells LLP (Firm Registration No. 117366W/W-100018) |
| Term of Appointment | Five (5) consecutive years |
| Effective Period | From the conclusion of the 36th AGM (2027) until the conclusion of the 41st AGM (2032) |
| Outgoing Auditor | M/s. B S R & Co. LLP |
The appointment of Deloitte Haskins & Sells LLP is subject to the approval of the company’s shareholders, which will be sought during the 36th AGM in 2027.
For reference, Deloitte Haskins & Sells, Mumbai, was constituted in 1997 and converted to a Limited Liability Partnership (LLP) with the name Deloitte Haskins & Sells LLP effective November 20, 2013. The firm is registered with the Institute of Chartered Accountants of India.
STAR Stock Price Movement
As of 3:00 PM, shares of Strides Pharma Science Limited are slipping by 2.27% in live trading, currently priced at ₹1127.5. Trading volume remains robust, with 956,694 shares transacting as the stock continues to weigh its intraday moves.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.